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Summary
 
By stimulating blood lymphocytes from a renal cell carcinoma patient in vitro with the autolo-
gous tumor cells, we obtained cytolytic T lymphocyte (CTL) clones that killed several autolo-
gous and allogeneic histocompatibility leukocyte antigen (HLA)-B7 renal carcinoma cell lines.
We identified the target antigen of these CTLs by screening COS cells transfected with the
HLA-B7 cDNA and with a cDNA library prepared with RNA from the tumor cells. The anti-
genic peptide recognized by the CTLs has the sequence LPRWPPPQL and is encoded by a
new gene, which we named 
 
RU2
 
. This gene is transcribed in both directions. The antigenic
peptide is not encoded by the sense transcript, RU2S, which is expressed ubiquitously. It is en-
coded by an antisense transcript, RU2AS, which starts from a cryptic promoter located on the
reverse strand of the first intron and ends up on the reverse strand of the RU2S promoter,
which contains a polyadenylation signal. This mechanism of antigen expression is unprece-
dented and further illustrates the notion that many peptides recognized by T cells cannot be
predicted from the primary structure of the major product of the encoding gene. Antisense
transcript RU2AS is expressed in a high proportion of tumors of various histological types. It is
absent in most normal tissues, but is expressed in testis and kidney, and, at lower levels, in uri-
nary bladder and liver. Short-term cultures of normal epithelial cells from the renal proximal
tubule expressed significant levels of RU2AS message and were recognized by the CTLs.
Therefore, this antigen is not tumor specific, but corresponds to a self-antigen with restricted
tissue distribution.
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S
 
everal antigens recognized by cytolytic T cells on hu-
man tumors have been defined (1). Although some of
them are expressed in various tumor types, most have been
characterized using antitumor CTLs isolated from the lym-
phocytes of melanoma patients. They can be classified ac-
cording to four groups: (a) shared tumor-specific antigens,
which are encoded by MAGE-type genes that are silent in
most normal tissues and expressed in many tumors; (b) me-
lanocyte differentiation antigens, such as tyrosinase, gp100,
and Melan-A
 
MART1
 
, which are also expressed in normal me-
lanocytes; (c) antigens resulting from tumor-specific point
mutations in genes expressed ubiquitously; and (d) antigens
that are overexpressed in tumor cells (for a review, see ref-
erence 1).
Because isolating CTLs against tumors other than mela-
noma is more difficult, little is known about the antigens
targeted by the immune system on such tumors. Three an-
tigens have been defined on renal cell carcinoma (RCC).
 
1
 
One corresponds to the first group of tumor antigens and is
encoded by gene 
 
RAGE
 
, which is silent in most normal
tissues but expressed only in a limited number of RCC
samples (2). The two other examples belong to the group
of mutated antigens and result from a point mutation in the
HLA-A2 or in the hsp70-2 gene (3, 4). Some CTLs against
RCC were also found to recognize normal kidney cells,
 
1
 
Abbreviations used in this paper:
 
 RACE, rapid amplification of cDNA ends;
RCC, renal cell carcinoma; RT, reverse transcription. 
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suggesting the recognition of kidney differentiation anti-
gens (5, 6). These antigens would be to kidney cancer what
melanocytic differentiation antigens are to melanoma. How-
ever, their molecular nature has not been defined. Here,
we provide the first definition of such a kidney differentia-
tion antigen. The mechanism of expression of this antigen
is very unusual: it is encoded by the reverse strand of a
housekeeping gene.
 
Materials and Methods
 
Cell Lines.
 
Cell lines LE9211-RCC, LE9211-EBV, and
LB23-SAR have been described previously (2). Lines LB2043-
PTEC and LB2046-PTEC were derived from surgical samples of
normal kidney cortex and grown in Iscove’s medium supple-
mented with ACL4 (7) and epithelial growth factor (10 ng/ml) (8).
They were confirmed to derive from the proximal tubule by test-
ing the expression of aquaporin-1 by immunohistochemistry (9).
Stable transfectant LB23-SAR-4.1 was obtained by transfection
of cDNA 4.1 cloned into plasmid pEF-BOSpuro-PL3 (10) using
the calcium phosphate precipitation method, selection with puro-
mycin, and cloning by limiting dilution. CTL clones were ob-
tained exactly as described (2).
 
CTL Assays.
 
Chromium-release and TNF stimulation assays
were performed as described previously (2). Before being used as
stimulators for a TNF assay, cells from LB2043- and LB2046-
PTEC were transiently transfected with the HLA-B7 cDNA us-
ing DMRIE-C (GIBCO BRL) according to the instructions of
the manufacturer. IFN-
 
g
 
 production was measured by ELISA us-
ing antibodies from Biosource.
 
Cloning of Gene RU2 and RU2 cDNAs.
 
We used the same
cDNA library as that described previously (2), using the proce-
dure detailed elsewhere (11). In brief, mRNA was converted to
cDNA with the Superscript Choice System (GIBCO BRL) using
an oligo-dT primer containing a NotI site at its 5
 
9
 
 end. cDNAs
were then ligated to BstXI adaptors and digested with NotI. After
size fractionation, the cDNAs were unidirectionally cloned into
the BstXI and NotI sites of plasmid pcDNAI/Amp (Invitrogen).
Plasmid DNA was purified from pools of 
 
z
 
100 independent
cDNA clones and transfected together with DNA from an HLA-B7
cDNA construct into COS cells by the DEAE-dextran-chloro-
quine method. Transfected COS cells were then screened for their
ability to stimulate the release of TNF by CTL 361A/21. The
5-terminal sequence was obtained by rapid amplification of cDNA
ends (RACE) PCR using the 5
 
9
 
 RACE System (GIBCO BRL).
The genomic library was prepared in phage vector lamb-
daGEM-11 (Promega Corp.) using standard techniques. Sequenc-
ing reactions were performed by PCR with the dideoxy-termina-
tion method and analyzed either manually or on an ABI310 Genetic
Analyzer (Perkin-Elmer Applied Biosystems).
 
PCR Assay.
 
Expression of RU2S and RU2AS was measured
by reverse transcription (RT)-PCR on cDNA produced from to-
tal RNA as described previously (2). Primers used were VDE87
and VDE93 for RU2S, and VDE119/VDE120 for RU2AS. PCR
conditions were: 5 min at 94
 
8
 
C, 35 cycles of 1 min at 94
 
8
 
C, 1 min
at 54
 
8
 
C for primers VDE87/VDE93 or at 62
 
8
 
C for primers
VDE119/VDE120, and 1 min at 72
 
8
 
C, and a final elongation
step of 15 min at 72
 
8
 
C. Primer sequences were: 5
 
9
 
-CCGTCAG-
GAACATCTACA-3
 
9
 
 (VDE87), 5
 
9
 
-CCAACAGCCACATAA-
AAC-5
 
9
 
 (VDE93), 5
 
9
 
-TAAATGGGTGGGCGGTGGGGGA-
GAC-3
 
9
 
 (VDE119), and 5
 
9
 
-TAGGCTGTTTGGAAAGGGT-
AGCACA-3
 
9
 
 (VDE120). Because primers VDE119 and VDE120
also amplify genomic DNA, positive samples were retested after
DNase treatment, to exclude any false positives due to DNA
contamination of the RNA samples. Control RT-PCRs were
also performed in which the addition of reverse transcriptase was
omitted during cDNA synthesis. For the quantitative PCR
shown in Fig. 8, the PCR conditions were first optimized to en-
sure linearity of the reaction according to De Plaen et al. (12).
Optimized conditions for primers VDE119/VDE120 were: 33
cycles with 1 min at 94
 
8
 
C, 2 min at 68
 
8
 
C, and 3 min at 72
 
8
 
C. Se-
rial twofold dilutions of each sample were then tested together
with dilutions of positive control sample LE9211-RCC, which
was chosen as a reference. PCR products were then visualized on
agarose gels stained with ethidium bromide, and the level of ex-
pression of each sample was inferred from the comparison with
the reference control. The results were then normalized for RNA
integrity by quantifying the actin message in the same way (12).
Results were expressed as percentages of the expression level
measured in reference sample LE9211-RCC.
 
Results
 
CTL clone 361/A21 was isolated by stimulating blood
lymphocytes of a kidney cancer patient in vitro with autol-
ogous tumor cells LE9211-RCC, and by cloning the re-
sponding cells by limiting dilution (13). This clone was able
to lyse both autologous and allogeneic tumor cells sharing
the HLA-B7 specificity, but it did not lyse autologous
EBV-transformed B cells or NK target K562 (Fig. 1). The
HLA-B7 restriction of this CTL clone was confirmed by
the observation that an anti–HLA-B7 antibody blocked the
recognition of the tumor cells (Fig. 2 A). To identify the
target antigen of CTL 361A/21, we prepared an oligo-
dT–based unidirectional cDNA library with RNA from
LE9211-RCC cells, and we transfected DNA from this li-
brary into COS cells together with DNA from an HLA-B7
cDNA plasmid construct. The transfected cells were screened
by adding the CTLs to the microcultures and measuring
the production of TNF. We isolated cDNA 4.1, which was
able to stimulate the CTLs when transfected into COS cells
together with the HLA-B7 cDNA (Fig. 2 B). This cDNA
Figure 1. Lytic activity of CTL clone 361A/21. The following target
cells were tested in a standard 4-h chromium-release assay: LE9211-
RCC, the autologous tumor line; MZ1851-RCC, an allogeneic HLA-
B7–positive renal cell carcinoma line; LE9211-EBV, autologous B cells
transformed with EBV; and K562, NK target cells. Results of a represen-
tative experiment are shown. CTL 361A/21 is representative of 12 CTL
clones isolated from the lymphocytes of patient LE9211 and recognizing
the same antigen. 
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clone was 924 bp long. Its sequence was new and con-
tained an open reading frame coding for a protein of 84
amino acids (Fig. 3). To exclude that recognition of the
transfected COS cells was an artifact of high expression lev-
els after transient transfection, we transfected an HLA-B7–
positive sarcoma line with cDNA 4.1. A stable transfectant
was obtained, and it was recognized by the CTLs (Fig. 4). To
identify the antigenic epitope recognized by CTL 361A/21,
we tested several synthetic peptides encoded by cDNA 4.1
and bearing the binding motif for HLA-B7, which is
 
 
 
P
 
 
 
in
position 2 and L/F in position 9 (14). We found that pep-
tide LPRWPPPQL was able to sensitize autologous EBV-B
cells to lysis by the CTLs (Fig. 5).
To obtain the full-length sequence of the transcript cor-
responding to cDNA 4.1, we amplified its 5
 
9
 
 end by PCR
and sequenced the product. This extended the 4.1 sequence
by 458 nucleotides (Fig. 3). The 1,382-bp sequence appeared
to represent the full-length message, since it corresponded
to a unique band observed by PCR amplification of the 5
 
9
 
end. However, when cDNA 4.1 was used as a double-
stranded probe on a Northern blot prepared with RNA from
LE9211-RCC cells, it hybridized with a band of 2.2 kb, sub-
stantially larger than our putative full-length sequence. To
solve this paradox, we screened our cDNA library by hy-
bridization using cDNA 4.1 as a double-stranded probe.
We obtained three identical clones of 2.2 kb, represented
by clone I.1. Remarkably, the coding strand of clone I.1
did not contain the sequence of the coding strand of cDNA
4.1, but contained a 595-bp sequence that was comple-
mentary to the coding strand of cDNA 4.1. Since both
cDNAs contained a poly(A) tail at their 3
 
9
 
 end and derived
from an unidirectional library, their coding strands appeared
to correspond to two genuinely distinct messages, one read
in the sense and the other in the antisense direction of the
same gene.
Figure 2. Isolation of a cDNA coding for the antigen recognized by
CTL 361A/21. (A) MHC restriction of CTL 361A/21. CTL activation
was followed by measuring the production of TNF after stimulation with
autologous tumor cells in the presence of the indicated anti-HLA mAbs.
The HLA typing of patient LE9211 is HLA-A3, -B7, -B35, -Cw4, and
-Cw7. MZ2-MEL is an allogeneic melanoma line that was used as a neg-
ative control. Antibodies W6/32 (anti–HLA class I), 4E (anti–HLA-B/C),
ME1 (anti–HLA-B7), and GAPA3 (anti–HLA-A3) were used as described
(reference 13). 3,000 CTLs were mixed with 30,000 tumor cells and IL-2
(25 U/ml), and TNF production was measured 18 h later as described else-
where (reference 11). (B) cDNA 4.1 cloned into plasmid pcDNAI/Amp
was transfected into COS cells together with the HLA-B*0702 cDNA
cloned into plasmid pcDSRalpha. CTL 361A/21 (3,000 cells) was added
after 24 h, and TNF production was measured 18 h later.
Figure 3. Sequence of transcript RU2AS and its predicted protein
product. The antigenic peptide recognized by CTL 361A/21 is under-
lined. The sequence shown is compiled from the sequence of cDNA 4.1
and the 59 sequence obtained by RACE PCR. The vertical arrows indi-
cate the limits of the fragment corresponding to the reverse strand of the
first exon of the gene (see Fig. 6). The horizontal arrows indicate primers
VDE119 (forward) and VDE120 (reverse), which were used for testing
the expression of RU2AS by RT-PCR. The RU2AS sequence is avail-
able from EMBL/GenBank/DDBJ under accession no. AF181722.
Figure 4. Lysis by CTL 361A/21 of LB23-SAR sarcoma cells trans-
fected with cDNA 4.1. A representative clone obtained after stable trans-
fection of cDNA 4.1 into HLA-B7 LB23-SAR sarcoma cells was used as
the target in a standard chromium-release assay with CTL 361A/21 as the
effector. Chromium release was measured after 4 h.
Figure 5. Lysis by CTL
361A/21 of LE9211-EBV cells
pulsed with synthetic peptide
LPRWPPPQL. Chromium-
labeled LE9211-EBV cells were
incubated with the indicated
peptide concentrations for 30
min before addition of CTLs at
an E/T ratio of 10. Chromium
release was measured after 4 h. 
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We cloned the genomic sequence by screening a phage
library constructed with genomic DNA from LE9211-
RCC cells, using cDNA 4.1 as a probe. We isolated a positive
phage containing a 14-kb insert, from which we sequenced
the relevant part. The comparison of the three sequences
revealed that cDNA I.1 corresponds to the fully spliced
transcript of the gene, whereas cDNA 4.1 corresponds to
an aberrant message that starts on the antisense strand of the
first intron, is transcribed backwards on the antiparallel strand
of exon 1, and ends with a polyadenylation site that is lo-
cated on the reverse strand of the promoter (Fig. 6). The
gene, which we called 
 
RU2
 
, is therefore transcribed in
both directions, producing a message of 2,167 bp on one
strand and another message of 1,382 bp on the other strand.
The longer message, which corresponds to cDNA I.1, ap-
pears to be the “normal” 
 
RU2 
 
message, since it encodes a
longer protein with potentially functional domains (Figs. 6
and 7) and is expressed at higher levels and in a wider range
of tissues (see below). We compared the sequence of the
 
RU2
 
 gene present in tumor cells LE9211-RCC to that of
the 
 
RU2
 
 gene present in autologous EBV-B cells and found
no mutation. By fluorescent in situ hybridization (FISH)
analysis, we mapped gene 
 
RU2
 
 to chromosome 6p22.1
(data not shown).
We tested the expression of the two opposite 
 
RU2
 
 tran-
scripts by RT-PCR. For the sense message, which we
named RU2S and which is represented by cDNA I.1, we
used primers located in different exons, as indicated in Fig.
6. We found that RU2S was expressed in all of the tissues
tested (Table I). This suggests a housekeeping function for
this gene, which is consistent with the presence of a CpG
island in its promoter and in most of exon 1 (Fig. 6).
We then tested the expression of the antisense transcript,
named RU2AS and represented by cDNA 4.1, using a
primer located in the promoter region and a primer located
in the first intron (Fig. 6). As opposed to the sense tran-
script, the antisense was only found in normal kidney, blad-
der, liver, and testis (Table I). However, a very high pro-
portion of tumors of various histological origins also express
RU2AS, including tumors derived from tissues that are
negative for RU2AS, such as melanomas, sarcomas, and
colorectal carcinomas (Table I).
To determine the level of expression of RU2AS in the
normal tissues that were found to be positive, we repeated
the RT-PCR using a limiting number of cycles and an op-
timized annealing temperature, to allow a quantitative am-
Figure 6. Partial structure of gene RU2.
Black boxes indicate the open reading
frames (ORF). The donor splice site of in-
tron 1 is shown. Potentially functional do-
mains of the RU2S protein are indicated.
The small arrows indicate the primers used
for testing the expression of the two op-
posite transcripts by RT-PCR: primers
VDE87 and VDE93 were used to detect ex-
pression of sense transcript RU2S, whereas
primers VDE119 and VDE120 were used to
detect antisense transcript RU2AS. The 39
part of intron 1 (dotted line) and the exons
that follow it were not sequenced. The ge-
nomic sequence of RU2 is available from
EMBL/GenBank/DDBJ under accession
no. AF181720.
Figure 7. Sequence of transcript RU2S (cDNA I.1) and its predicted
protein product. The vertical arrow indicates the end of the first exon.
The horizontal arrows indicate primers VDE87 (forward) and VDE93
(reverse), which were used for testing the expression of RU2S by RT-
PCR. The RU2S sequence is available from EMBL/GenBank/DDBJ
under accession no. AF181721. 
1797
 
Van den Eynde et al.
 
plification of the messenger RNA (15). The results shown
in Fig. 8 are expressed as percentages of the level of expres-
sion found in cell line LE9211-RCC, which is arbitrarily
considered as expressing 100% of RU2AS. We found that
testis expresses 16–31%, kidney 7–19%, and bladder and
liver 6%.
We previously observed, with a CTL clone directed
against a MAGE-1 peptide, that cell lines expressing the
MAGE-1 mRNA below a threshold of 
 
z
 
10% were not
recognized by the CTLs (15).
 
 
 
Therefore, to determine
whether the level of RU2AS in normal kidney is above the
threshold for CTL recognition, we derived short-term cell
lines from two samples of normal kidney.
 
 
 
These two lines
appeared to derive from the proximal tubule epithelium,
since they expressed aquaporin-1, a specific marker of those
tubules (9; data not shown). We measured the level of
RU2AS in those lines by RT-PCR, and found that line
LB2043-PTEC expressed 50% of the control level, whereas
LB2046-PTEC expressed 25%. We then tested those cell
lines for recognition by CTL 361A/21, after transient
transfection of the HLA-B7 cDNA. As shown in Fig. 9,
both lines were able to stimulate the production of IFN-
 
g
 
by the CTLs. Line LB2043-PTEC was also recognized
without transfection of HLA-B7, suggesting that it already
expressed the HLA-B7 molecule. We conclude that this
antigen is not tumor specific and is expressed in at least a
subtype of normal kidney cells.
Expression of antisense transcripts is well known in
prokaryotes, where it constitutes an important mechanism
of gene regulation (16). Recently, several natural antisense
RNA were also described in eukaryotes. They are believed
to control gene expression, either by targeting the sense
transcript for rapid degradation or by preventing its transla-
tion (for a review, see reference 17). To find out whether
the two opposite RU2 transcripts exert a similar regulatory
role, we transfected COS cells with the HLA-B7 cDNA
and with both the sense and the antisense cDNAs at various
ratios. We found that a 200-fold excess of RU2S over
 
Table I.
 
Expression of the Sense (RU2S) and Antisense (RU2AS) Transcripts of Gene RU2
 
Expression of transcript
No. of tumors expressing RU2AS/
No. of tumors tested Normal tissues RU2S RU2AS Tumor samples
Adrenals
 
12
 
Renal carcinomas 10/10
Breast
 
12
 
Colorectal carcinomas 14/15
Colon
 
12
 
Melanomas 15/24
Heart
 
62
 
Sarcomas 7/9
Kidney
 
11
 
Leukemias 12/18
Liver
 
11
 
Brain tumors 6/9
Lung
 
12
 
Thyroid carcinomas 4/5
Ovary
 
12
 
Mammary carcinomas 5/10
Prostate
 
12
 
Prostatic carcinomas 4/10
Skin
 
12
 
Esophageal tumors 3/9
Stomach
 
12
 
Bladder tumors 3/10
Testis
 
11
 
Lung carcinomas 4/20
Urinary bladder
 
16
 
Head and neck tumors 1/10
Uterus
 
12
 
Mesotheliomas 0/4
Expression was measured by RT-PCR as indicated in Materials and Methods.
Figure 8. Quantification of transcript RU2AS by RT-PCR. The level
of RU2AS transcript in the indicated normal tissues was measured by
RT-PCR as described in Materials and Methods and is expressed as per-
centage of the level of RU2AS found in LE9211-RCC tumor cells. 
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RU2AS did not prevent recognition of the transfected cells
by our CTLs directed against the RU2AS-encoded pep-
tide, indicating that an excess of sense transcript does not
significantly affect stability and translation of the antisense
transcript (data not shown).
 
Discussion
 
Our results contribute to the dissection of the immune
response against renal cancer cells and provide the first mo-
lecular definition of the antigenic target of CTLs recogniz-
ing both normal and tumoral kidney cells. Such CTLs have
been isolated from several patients by different groups, and
they represent an important part of the T cell response
against kidney cancer, at least in vitro
 
 
 
(5, 6). In one case,
such CTLs were isolated from the lymphocytes of a patient
who had been successfully treated with IL-2/LAK therapy,
suggesting a possible in vivo relevance of this type of im-
mune response (6). Interestingly, this patient did not show
clinically detectable signs of autoimmunity despite the
complete tumor response and the presence in his blood of
CTLs against normal kidney cells. However, whether kid-
ney differentiation antigens can be successfully and safely
used for cancer immunotherapy is as yet uncertain.
The mechanism of expression of the RU2AS antigen is
unprecedented and further supports the notion that many
antigens recognized by T cells cannot be predicted from
the primary structure of the major product of the encoding
gene, but rather result from nonclassical mechanisms acting
at the level of transcription, translation, or processing (18).
One of the first such examples was a melanoma antigenic
peptide, which was found to be encoded by the intronic
part of an aberrant transcript starting on a cryptic promoter
in an intron of the gene coding GnTV, a ubiquitous en-
zyme involved in protein glycosylation (19). This mecha-
nism resembles that of RU2AS, except that the cryptic
promoter is located on the sense and not the antisense
strand of the intron. Other antigens have been found to
be encoded by retained introns resulting from splicing
defects in the 
 
MUM-1
 
, gp100, and 
 
TRP2
 
 genes (20–22).
Translation of alternative open reading frames of genes
 
TRP1
 
 and 
 
NY-ESO-1
 
 was also found to provide antigenic
peptides recognized by CTLs on melanoma (23–25). Fi-
nally, a tyrosinase peptide was found to be modified after
translation, with the asparagine residue of a glycosylation
site changed into an aspartic acid, apparently after removal
of the glucid moiety before processing of the peptide by
the proteasome (26).
Altogether, these findings indicate that the variety of pep-
tides presented to T lymphocytes is larger than expected, and
that some potentially useful antigens cannot be predicted
from the sequence of the cellular protein content.
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